Cryo-Cell International, Inc.

NYSE American CCEL

Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending August 31, 2024: -34.82%

Cryo-Cell International, Inc. EBITDA Margin is -34.82% for the Trailing 12 Months (TTM) ending August 31, 2024, a -270.86% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending August 31, 2023 was 20.38%, a 32.78% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending August 31, 2022 was 15.35%, a -45.49% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending August 31, 2021 was 28.15%, a 36.77% change year over year.
Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending August 31, 2020 was 20.58%, a 14.23% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NYSE American: CCEL

Cryo-Cell International, Inc.

CEO	Mr. David I. Portnoy
IPO Date	April 4, 1994
Location	United States
Headquarters	700 Brooker Creek Boulevard
Employees	82
Sector	Healthcare
Industries Biotechnology 3D Printing Baby & Childcare Containers & Packaging Frozen Foods Medical Instruments Personal Care Plastics

Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key trends

Past 5 years